Sign In
Buy BGNE
$184.71
+0 (+0%)
At Close: Mar 28, 2025
Week In Review: BeiGene Plans $2.5 Billion IPO On Shanghai Star Exchange
11:34am, Sunday, 22'nd Nov 2020
BeiGene is planning an IPO on the Shanghai Star Exchange that could raise up to $2.5 billion. BeiGene announced China approval to market Xgeva (denosumab) to prevent skeletal-related events (SREs) in
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces the second approval of XGEVA® (denosumab) in China.
CAMBRIDGE, Mass. & BEIJING, China--(BUSINESS WIRE)---- $BGNE #BGNE--Global Phase 3 trial of tislelizumab in second- or third-line non-small cell lung cancer met the primary endpoint at interim analysi
Week In Review: RemeGen, A Yantai Biologics Company, Completes $515 Million Hong Kong IPO
12:33pm, Sunday, 15'th Nov 2020
Innoforce, a Hangzhou company, formed a JV with Thermo Fisher Scientific to build a large biologics and steriles drug development and manufacturing facility in the Hangzhou Airport Economic Demonstrat
EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for QARZIBA®▼ (Dinutuximab Beta) in China
07:04am, Monday, 09'th Nov 2020
HEMEL HEMPSTEAD, England & BEIJING, China, & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that the Biologics License Applic
Week In Review: Antengene Approved By Hong Kong Exchange For $200 Million IPO
01:48pm, Sunday, 30'th Aug 2020
Antengene, a three-year old Shanghai startup originally backed by Celgene, will conduct a Hong Kong IPO that is expected to raise $200 million.
BeiGene COVID-19 Deal And Other News: The Good, Bad And Ugly Of Biopharma
04:22am, Sunday, 30'th Aug 2020
BeiGene signs deal with Singlomics for neutralizing COVID-19 antibodies. UroGen flunks Phase 2 RTGel combo study.
Insider Weekends: Chuck Davis Purchases $60 Million Worth Of AXIS Capital
06:05pm, Sunday, 23'rd Aug 2020
Insider buying decreased last week. Notable Insider Buys: AXIS Capital Holdings Limited, Red Rock Resorts, Inc., Kinder Morgan, Inc., Live Oak Bancshares, Inc., Verrica Pharmaceuticals Inc.
What Makes BeiGene, Ltd. (BGNE) a New Buy Stock
04:00pm, Friday, 07'th Aug 2020
BeiGene, Ltd. (BGNE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
BeiGene Reports Second Quarter 2020 Financial Results
08:05pm, Thursday, 06'th Aug 2020
CAMBRIDGE, Mass. and BEIJING, China, Aug. 06, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing inn
CAMBRIDGE, Mass. and BEIJING, China, Aug. 05, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing inn
Priority Review Granted to BeiGene’s New Drug Application of Pamiparib in Ovarian Cancer in China
01:15pm, Monday, 27'th Jul 2020
BEIJING, China and CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company, today announced that the Center for Drug Eva
Insider Weekends: CEO Of Guess Buys $1 Million Worth Of Stock
04:34am, Monday, 27'th Jul 2020
Insider buying decreased last week. Notable Insider Buys: Guess’, Inc., FedEx Corporation, American Virtual Cloud Technologies, Inc., Saratoga Investment Corp., The Charles Schwab Corporation.
Week In Review: BeiGene Signs $540 Million Deal For China Rights To 3 HBV Candidates
12:07pm, Sunday, 26'th Jul 2020
Beijing's BeiGene in-licensed Greater China rights to three inhibitors for chronic hepatitis B virus from Assembly Biosciences in a $540 million agreement.
13Ds Filings
10:12pm, Friday, 24'th Jul 2020
Activist reports to the SEC from July 16 through July 22, 2020, including positions in Anterix, Inventiva, BeiGene, and two other companies
